Navigation Links
Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
Date:3/10/2008

00 U/kg (30 mg/kg) were well-tolerated following either IV or SC

dosing.

-- Daily administration of rHuPH20 for one week was well tolerated via

either IV or SC delivery at a daily bolus dose of 600,000 U/kg

(5 mg/kg). No test article-related changes were observed in any

toxicology parameters and no systemic enzyme accumulation was observed.

-- A 3-month interim analysis from an ongoing 39-week chronic toxicity

study with weekly dosing up to 240,000 U/kg revealed no changes in

standard toxicity parameters or in male fertility assessment.

"These studies further expand the safety database for rHuPH20 in both dose and duration, and support the potential use of rHuPH20 from Halozyme's new manufacturing process in chronic applications," said Walter Bee, PhD, Halozyme's Vice President of Preclinical Development. "We anticipate that this toxicology package will be supportive of our current and future Enhanze(TM) Technology partners' regulatory applications."

About Enhanze Technology

Enhanze Technology is Halozyme's proprietary drug delivery technology based on recombinant human hyaluronidase (rHuPH20), a recombinant form of the naturally occurring human enzyme being investigated for its ability to break down hyaluronic acid (HA), the space-filling "gel"-like substance that is a major component of tissues throughout the body. When combined or co-formulated with certain injectable drugs, Enhanze(TM) Technology can act as a "molecular machete" to facilitate the penetration and dispersion of these drugs by temporarily opening flow channels under the skin. Molecules as large as 200 nanometers may pass freely through the perforated extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
2. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
3. Halozyme Therapeutics Amends Stockholder Rights Plan
4. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
5. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
6. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
7. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
8. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
9. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
11. ExonHit Therapeutics - 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines (NASDAQ: ... its initial public offering of 9,367,708 shares of ... $18.00 per share, including shares of common stock ... of their option to purchase additional shares. The ... Blueprint Medicines were approximately $168.6 million, before underwriting discounts ...
(Date:5/5/2015)... 2015 VetStem Biopharma, proudly announces ... Jeffrey Schaffer, DVM, as Director of Veterinary Professional ... of experience in the veterinary regenerative medicine field ... our veterinarian lead organization”. Dr. Alexis Nahama, ... will be responsible for all technical activities in ...
(Date:5/5/2015)... Israel , May 5, 2015  Tikcro ... Company was approved to continue trading on OTCQB  ... OTCQB Marketplace allows for a continuous ... broker-dealers. Investors can have real-time quotes and market ... The OTCQB Marketplace includes U.S. and ...
(Date:5/5/2015)... NEW YORK , May 5, 2015 /PRNewswire/ ... today announced that Andrew Gengos , President and ... on May 7, 2015. DATE:  Thursday, May ... LINK:  http://VirtualInvestorConferences.com > click the ... will be a live, interactive online event where ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2
... 11 Schering-Plough,Corporation (NYSE: SGP ) today announced ... of a New Drug Application (NDA) for ZEGERID(R),(omeprazole/sodium bicarbonate) ... a branded over-the-counter (OTC) product to treat frequent,heartburn., ... license agreement with,Santarus, Inc. of San Diego, Calif., which ...
... analysis affordable and accessible to all researchers, ... today that Harvard Medical School and the University ... Program. Each University,purchased access to whole genome human ... Consortium and distributed by Open Biosystems., (Logo: ...
... China,Bionanometer Industries Corporation (Pink Sheets: CBIU), a ... signed an agreement to,establish long-term strategic cooperative ... Guangzhou LGLY Advertising LTD is China,s top ... and is well-known for its core senior ...
Cached Biology Technology:Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 2Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 3Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina 2CBIU Signs Agreement with LGLY Advertising LTD 2
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... Deamer began studying the origin of life in the early ... had a major influence on scientific understanding of how life ... (UC Press, June 2011), Deamer presents a personal history of ... and accessible overview of research into life,s beginnings. ...
... of the 2010 Nobel Prize in Chemistry, will be ... Chemistry and Engineering Conference, June 21-23, in Washington, D.C. ... Hilton Hotel, just two blocks north of the White ... around the world, is sponsored by the American Chemical ...
... 2011) New research suggests an effective recovery drink ... Grabbing lowfat chocolate milk after a tough workout helped ... advantage, according to three new studies presented at the ... Journal of Strength and Conditioning Research this ...
Cached Biology News:Biochemist David Deamer explores how life began in new book, 'First Life' 2Nobel Laureate to speak at American Chemical Society green chemistry conference 2New research: Post-exercise recovery advantages of lowfat chocolate milk 2